An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients-Reference-Cited by-同舟云学术

An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

Published:2024-04 Issue: Volume:224 Page:105835
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Debing Yannick^ORCID,Vanrusselt Hannah^ORCID,Degrauwe Lars^ORCID,Silva de Oliveira Daniel Apolônio,Kariuki Christopher Kinyanjui^ORCID,Ebwanga Ebanja Joseph,Bashir Shahbaz,Merckx Wouter,Thatikonda Santhosh Kumar,Rajwanshi Vivek,Gohil Vikrant,Hong Jin,Kum Dieudonné Buh,Acosta Sanchez Abel,Chanda Sushmita,Blatt Lawrence M.,Jekle Andreas,Symons Julian A.,Smith David B.,Raboisson Pierre,Lin Tse-I,Beigelman Leonid,Paeshuyse Jan^ORCID

Funder

Agentschap Innoveren en Ondernemen

Publisher

Elsevier BV

Reference21 articles.

1. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection;Al-Mahtab;PLoS One,2016

2. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection;Bazinet;Hepatol. Commun.,2020

3. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy;Bazinet;Gastroenterology,2020

4. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells;Blanchet;Antivir. Res.,2019

5. Rescue of cirrhotic HBV/HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg;Bourlière,2023